Rocatinlimab Demonstrates Significant Efficacy in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis
Key Insights
Two global phase 3 trials (ROCKET-IGNITE and ROCKET-HORIZON) demonstrated that rocatinlimab significantly improved clinical signs of moderate-to-severe atopic dermatitis (search) at 24 weeks compared with placebo.
The 300 mg dose achieved EASI-75 response rates of 42% in IGNITE and 33% in HORIZON, representing significant improvements over placebo rates of 13% and 14% respectively.
Rocatinlimab targets memory T cells through the OX40 (search) pathway, offering the first phase 3 proof that rebalancing immune cells can transform atopic dermatitis (search) treatment.
Two pivotal phase 3 clinical trials have demonstrated that rocatinlimab, a novel immunomodulatory therapy targeting the OX40 (search) pathway, significantly improves clinical outcomes in adults with moderate-to-severe atopic dermatitis (search) compared to placebo. The ROCKET-IGNITE and ROCKET-HORIZON studies, conducted across 19 countries each, represent a major advancement in understanding how immune cell rebalancing can transform eczema (search) treatment.
Trial Design and Patient Population
Both studies enrolled adults aged 18 years and older with confirmed atopic dermatitis (search) for at least one year, meeting specific severity criteria including an Eczema (search) Area and Severity Index (EASI) score of 16 or higher, validated Investigator's Global Assessment for AD (vIGA-AD) score of 3-4, and at least 10% affected body surface area.
The IGNITE trial randomized 767 participants in a 3:2:2 ratio to receive subcutaneous rocatinlimab 300 mg (n=328), 150 mg (n=217), or placebo (n=222). The HORIZON trial used a 3:1 randomization, with 543 participants receiving rocatinlimab 300 mg and 183 receiving placebo. Treatment was administered at weeks 0, 2, and 4, then every 4 weeks through week 20, with efficacy assessed at week 24.
Primary Efficacy Outcomes
Both trials met all coprimary endpoints with statistically significant improvements for rocatinlimab versus placebo. The coprimary endpoints were EASI-75 response (≥75% improvement) and vIGA-AD score of 0-1 with ≥2-point improvement, each evaluated at week 24.
EASI-75 Response Rates
In the IGNITE trial, the 300 mg dose achieved a 42% EASI-75 response rate compared to 13% with placebo, representing a 29.5% difference (95% CI, 22.3-36.1; P<.001). The 150 mg dose demonstrated a 36% response rate versus placebo, with a 23.4% difference (95% CI, 15.4-30.9; P<.001).
The HORIZON trial showed a 33% EASI-75 response rate for the 300 mg dose compared to 14% with placebo, yielding a 19.1% difference (95% CI, 12.4-25.2; P<.001).
vIGA-AD Clear or Almost Clear Response
For the vIGA-AD endpoint in IGNITE, the 300 mg dose achieved a 24% response rate versus 9% with placebo, representing a 14.9% difference (95% CI, 8.8-20.6; P<.001). The 150 mg dose showed a 19% response rate with a 10.3% difference versus placebo (95% CI, 3.8-16.6; P=.002).
In HORIZON, the 300 mg dose demonstrated a 19% vIGA-AD response rate compared to 7% with placebo, showing a 12.8% difference (95% CI, 7.6-17.3; P<.001).
Novel Mechanism of Action
According to lead author Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, rocatinlimab represents "the first phase 3 proof that rebalancing these immune cells can transform how we treat atopic dermatitis (search)." The therapy targets memory T cells through the OX40 (search) pathway, offering a distinct approach to managing the underlying immune dysfunction in atopic dermatitis.
Safety Profile
Treatment-emergent adverse event rates were generally similar between rocatinlimab and placebo groups in both studies. The most common adverse events occurring in ≥4% of participants and at ≥2 times placebo frequency included pyrexia (12% with 300 mg, 12% with 150 mg), chills (6% with 300 mg, 2% with 150 mg), and aphthous ulcers (4% with 300 mg, 3% with 150 mg).
Investigators noted that most pyrexia and chills events were injection-related, occurred primarily after the first dose, and were mild or moderate in severity. Serious adverse events occurred in 2%-5% of rocatinlimab-treated participants compared to 4%-6% of placebo-treated participants. Importantly, no deaths were reported in either study.
Clinical Implications
Dr. Guttman-Yassky emphasized the significance of these findings, stating, "These findings represent a major advance for patients living with eczema (search), who often face years of uncontrolled symptoms and few effective options. By targeting memory T cells through OX40 (search), rocatinlimab not only clears the skin and relieves itch, but continues to improve patients' lives over time with a strong safety profile."
The results from both ROCKET trials establish rocatinlimab as a promising therapeutic option for adults with moderate-to-severe atopic dermatitis (search), offering a novel mechanism of action that addresses the underlying immune pathophysiology of the disease while maintaining an acceptable safety profile.